Results 31 to 40 of about 696 (142)

Langerhans cells increase their expression of integrin αvβ8 through migration and are needed for Tregs induction by epicutaneous immunotherapy (EPIT) [PDF]

open access: bronzeJournal of Allergy and Clinical Immunology, 2019
Vincent Dioszeghy   +7 more
openalex   +2 more sources

Eating away at food allergy. [PDF]

open access: yesPediatr Allergy Immunol
Fitness/endurance as an analogy to food desensitization. Both involve exposing the body to an activity initially poorly tolerated to gain capacity: In food treatments this is the capacity to eat more of the food and in exercise it is the capacity to exercise. When viewed as such it may not be surprising that with most currently available treatments the
Du YJ, Guo JC, Upton JEM.
europepmc   +2 more sources

Safety of Viaskin Milk Epicutaneous Immunotherapy (EPIT) in IgE-Mediated Cow's Milk Allergy (CMA) in Children (MILES Study) [PDF]

open access: closedJournal of Allergy and Clinical Immunology, 2016
Karine Rutault   +9 more
openalex   +2 more sources

Enhanced Efficacy and Confirmed Safety of a Two-Year Epicutaneous Immunotherapy (EPIT) Treatment of Peanut Allergy with Viaskin® Peanut: The Continuation of the Vipes Phase IIb Randomized Controlled Trial (RCT) [PDF]

open access: bronzeJournal of Allergy and Clinical Immunology, 2016
Hugh A. Sampson   +19 more
openalex   +2 more sources

Epicutaneous immunotherapy for the treatment of peanut allergy. [PDF]

open access: yesAllergy
Abstract Peanut allergy treatment options remain limited, but novel approaches are being studied, including epicutaneous immunotherapy (EPIT). EPIT uses the cutaneous immune system to promote tolerance to food allergens. Viaskin™ Peanut, an approach to EPIT in late‐stage clinical development uses an occlusive patch with a condensation chamber that ...
Ravindran M   +5 more
europepmc   +2 more sources

A Streamlined Approach to Basophil Activation Testing for Longitudinal Characterization of Toddlers with Peanut Allergy During a Multi-Site Phase 3 Double-Blind Placebo-Controlled Trial of Epicutaneous Immunotherapy (EPIT) [PDF]

open access: bronzeJournal of Allergy and Clinical Immunology
Alexander Grishin   +7 more
openalex   +2 more sources

Long-term Safety Results of Epicutaneous Immunotherapy (EPIT) with Viaskin Peanut in Peanut-Allergic Children Aged 4-11 Years in the Phase 3 PEOPLE Study [PDF]

open access: bronzeJournal of Allergy and Clinical Immunology
David E. Fleischer   +7 more
openalex   +2 more sources

Efficacy and Safety of Long-Term Epicutaneous Immunotherapy (EPIT) Treatment of Peanut Allergy with Viaskin® peanut: Results of the Two-Year Extension of the Vipes Phase IIb Clinical Trial [PDF]

open access: closedJournal of Allergy and Clinical Immunology, 2017
Wayne G. Shreffler   +4 more
openalex   +2 more sources

The Role of Regulatory T Cells in Epicutaneous Immunotherapy for Food Allergy

open access: yesFrontiers in Immunology, 2021
In recent decades, a rapid increase in the prevalence of food allergies has led to extensive research on novel treatment strategies and their mechanisms.
Guirong Liu   +4 more
doaj   +1 more source

Allergen immunotherapy for IgE-mediated food allergy: a systematic review and meta-analysis [PDF]

open access: yes, 2017
Background: The European Academy of Allergy and Clinical Immunology (EAACI) is developing Guidelines for Allergen Immunotherapy (AIT) for IgE-mediated Food Allergy.
Dhami, Sangeeta   +2 more
core   +9 more sources

Home - About - Disclaimer - Privacy